Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961348 | 1.00 | HSD11B1 (1.00) | HSD11B1RAB9AEPHX2ALDH1A1TSHR | |
| SCHEMBL29393737 | 1.00 | HSD11B1 (1.00) | HSD11B1RAB9AEPHX2ALDH1A1TSHR | |
| SCHEMBL612794 | 1.00 | HSD11B1 (1.00) | HSD11B1RAB9AEPHX2ALDH1A1TSHR | |
| SCHEMBL612171 | 1.00 | HSD11B1 (1.00) | HSD11B1RAB9AEPHX2ALDH1A1TSHR | |
| SCHEMBL4962053 | 0.99 | HSD11B1 (0.98) | HSD11B1RAB9AEPHX2ALDH1A1TSHR | |
| SCHEMBL611305 | 0.99 | HSD11B1 (0.98) | HSD11B1RAB9AEPHX2ALDH1A1TSHR | |
| SCHEMBL5950314 | 0.95 | HSD11B1 (0.90) | HSD11B1RAB9AEPHX2TSHR | |
| SCHEMBL5950609 | 0.95 | HSD11B1 (0.90) | HSD11B1RAB9AEPHX2TSHR | |
| SCHEMBL4007664 | 0.95 | HSD11B1 (0.90) | HSD11B1RAB9AEPHX2TSHR | |
| SCHEMBL4010679 | 0.95 | HSD11B1 (0.90) | HSD11B1RAB9AEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | claimed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | claimed |
| EP-1758580-A4 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1758580-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006012226-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2020128529-A1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI BIO LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020128529-A1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI BIO LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019186171-A1 | TREATMENT OF SARCOPENIC DISEASES | BENEVOLENTAI BIO LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| WO-2016164413-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010121814-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST | ONTOCHEM GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | disclosed |
| EP-1758580-A4 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1758580-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006012226-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | HSD11B1 1/4885RAB9A 2691/4885EPHX2 1175/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885RAB9A 2077/4885EPHX2 1552/4885 |
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | HSD11B1 241/4885RAB9A 2740/4885EPHX2 3280/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | HSD11B1 214/4885RAB9A 3047/4885EPHX2 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.